Aarkstore - CountryFocus Healthcare, Regulatory and Reimbursement Landscape – Denmark
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Denmark. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.
Denmark’s population in 2013 was approximately 5.6 million, having grown at a Compound Annual Growth Rate (CAGR) of 0.5% from 2008. Denmark has a national health insurance scheme, which ensures that all of its residents have access to treatment and health services, regardless of age, income and health. In 2013, the government spent approximately $1.5 trillion on R&D and exported approximately $1.6 trillion of pharmaceutical products. The pharmaceutical market was worth $3.9 billion in 2008 and is projected to reach $3.0 billion by 2020, declining at a CAGR of 2.2%. Although the pharmaceutical market steadily increased in local currency terms between 2008 and 2013, it decreased in US dollar terms, owing to currency devaluation. The medical device market was valued at $1.3 billion in 2008 and is projected to grow at a CAGR of 4.8% to $2.3 billion in 2020, primarily attributed to -
- An increasingly elderly population
- Universal health coverage
- Government initiatives